基于母体特征、生物物理与生化标志物预测整个妊娠期子痫前期:一项纵向研究
该纵向病例-队列研究纳入1150例孕妇,采用母体特征、既往风险评分及平均动脉压、胎盘生长因子、可溶性血管内皮生长因子受体-1、可溶性内皮糖蛋白,建立并评估贯穿妊娠各期的子痫前期预测模型。结果:早产型子痫前期在28至31+6周敏感度达84%(假阳性率10%),足月型子痫前期在32至36+6周敏感度为51%(假阳性率10%);加入可溶性内皮糖蛋白使20至23+6周对重叠型子痫前期的早期预测敏感度由44%升至54%。
要点
- 联合既往风险评分与平均动脉压、胎盘生长因子、可溶性血管内皮生长因子受体-1、可溶性内皮糖蛋白可预测子痫前期。
- 早产型子痫前期敏感度随孕周升高,28至31+6周达84%(假阳性率10%)。
- 加入可溶性内皮糖蛋白使20至23+6周重叠型子痫前期敏感度由44%升至54%。
核心结论
- 作者提出了贯穿整个妊娠期的子痫前期预测模型,可用于早孕期识别可从阿司匹林治疗中获益的高危孕妇,或用于妊娠后期辅助患者管理。
- 与8至15+6周的预测性能相比,使用20周后及32周后收集的数据分别使早产型和足月型子痫前期的检出率明显提高。
- 血浆可溶性内皮糖蛋白的纳入改善了重叠型子痫前期的早期预测,在无法进行子宫动脉多普勒测速时可能有价值。
研究设计与样本
- 纵向病例-队列研究,纳入1150例孕妇:无子痫前期且无慢性高血压者871例、无子痫前期但有慢性高血压者49例、发生子痫前期者166例、发生重叠型子痫前期者64例。
- 平均动脉压及基于免疫测定的母体血浆胎盘生长因子、可溶性血管内皮生长因子受体-1、可溶性内皮糖蛋白浓度贯穿妊娠期可获得(每例中位5次观测)。
- 采用泊松回归基于母体特征与产科病史建立子痫前期既往风险模型,并以多元回归在8至15+6、16至19+6、20至23+6、24至27+6、28至31+6、32至36+6周各时间区间将标志物数据转换为均值倍数。
- 基于标志物均值倍数与既往风险估计拟合子痫前期多变量预测模型,分别针对总体、早产型和足月型子痫前期建模,并以受试者工作特征曲线及固定假阳性率下的敏感度评估。
主要发现
- 在所有子痫前期预测模型中加入可溶性内皮糖蛋白(连同既往风险估计、平均动脉压、胎盘生长因子、可溶性血管内皮生长因子受体-1)提高了重叠型子痫前期早期预测的敏感度(假阳性率固定10%),最大增幅出现在20至23+6周,由44%升至54%(McNemar检验,P<.05)。
- 既往风险估计与标志物联合预测早产型子痫前期,假阳性率10%时敏感度在8至15+6、16至19+6、20至23+6、24至27+6、28至31+6周分别为55%、48%、62%、72%、84%。
- 足月型子痫前期假阳性率10%时敏感度在8至15+6、16至19+6、20至23+6、24至27+6、28至31+6、32至36+6周分别为36%、36%、41%、43%、39%、51%。
- 慢性高血压女性的重叠型子痫前期检出率与无慢性高血压女性相似,尤其在妊娠早期,20至23+6周最高为54%(假阳性率10%)。
- 当使用相同的母体风险因素和标志物(平均动脉压、胎盘生长因子、可溶性血管内皮生长因子受体-1均值倍数)作为输入时,预测模型的表现与胎儿医学基金会计算器相当。
关键数值与推荐
- 早产型子痫前期联合预测敏感度(假阳性率10%):8至15+6周55%、16至19+6周48%、20至23+6周62%、24至27+6周72%、28至31+6周84%。
- 足月型子痫前期联合预测敏感度(假阳性率10%):8至15+6周36%、16至19+6周36%、20至23+6周41%、24至27+6周43%、28至31+6周39%、32至36+6周51%。
- 加入可溶性内皮糖蛋白后重叠型子痫前期20至23+6周敏感度由44%升至54%(假阳性率10%,McNemar检验P<.05)。
- 慢性高血压女性重叠型子痫前期检出率与无慢性高血压女性相似,20至23+6周最高54%(假阳性率10%)。
临床怎么用
- 作者认为这些模型可用于早孕期识别可从阿司匹林治疗中获益的高危孕妇,或用于妊娠后期辅助患者管理。
- 作者认为血浆可溶性内皮糖蛋白的加入改善重叠型子痫前期早期预测,在无法进行子宫动脉多普勒测速时可能有价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current approach to predict preeclampsia combines maternal risk factors and evidence from biophysical markers (mean arterial pressure, Doppler velocimetry of the uterine arteries) and maternal blood proteins (placental growth factor, soluble vascular endothelial growth factor receptor-1, pregnancy-associated plasma protein A). Such models require the transformation of biomarker data into multiples of the mean values by using population- and site-specific models. Previous studies have focused on a narrow window in gestation and have not included the maternal blood concentration of soluble endoglin, an important antiangiogenic factor up-regulated in preeclampsia. OBJECTIVE: This study aimed (1) to develop models for the calculation of multiples of the mean values for mean arterial pressure and biochemical markers; (2) to build and assess the predictive models for preeclampsia based on maternal risk factors, the biophysical (mean arterial pressure) and biochemical (placental growth factor, soluble vascular endothelial growth factor receptor-1, and soluble endoglin) markers collected throughout pregnancy; and (3) to evaluate how prediction accuracy is affected by the presence of chronic hypertension and gestational age. STUDY DESIGN: This longitudinal case-cohort study included 1150 pregnant women: women without preeclampsia with (n=49) and without chronic hypertension (n=871) and those who developed preeclampsia (n=166) or superimposed preeclampsia (n=64). Mean arterial pressure and immunoassay-based maternal plasma placental growth factor, soluble vascular endothelial growth factor receptor-1, and soluble endoglin concentrations were available throughout pregnancy (median of 5 observations per patient). A prior-risk model for preeclampsia was established by using Poisson regression based on maternal characteristics and obstetrical history. Next, multiple regression was used to fit biophysical and biochemical marker data as a function of maternal characteristics by using data collected at 8 to 15+6, 16 to 19+6, 20 to 23+6, 24 to 27+6, 28 to 31+6, and 32 to 36+6 week intervals, and observed values were converted into multiples of the mean values. Then, multivariable prediction models for preeclampsia were fit based on the biomarker multiples of the mean data and prior-risk estimates. Separate models were derived for overall, preterm, and term preeclampsia, which were evaluated by receiver operating characteristic curves and sensitivity at fixed false-positive rates. RESULTS: (1) The inclusion of soluble endoglin in prediction models for all preeclampsia, together with the prior-risk estimates, mean arterial pressure, placental growth factor, and soluble vascular endothelial growth factor receptor-1, increased the sensitivity (at a fixed false-positive rate of 10%) for early prediction of superimposed preeclampsia, with the largest increase (from 44% to 54%) noted at 20 to 23+6 weeks (McNemar test, P<.05); (2) combined evidence from prior-risk estimates and biomarkers predicted preterm preeclampsia with a sensitivity (false-positive rate, 10%) of 55%, 48%, 62%, 72%, and 84% at 8 to 15+6, 16 to 19+6, 20 to 23+6, 24 to 27+6, and 28 to 31+6 week intervals, respectively; (3) the sensitivity for term preeclampsia (false-positive rate, 10%) was 36%, 36%, 41%, 43%, 39%, and 51% at 8 to 15+6, 16 to 19+6, 20 to 23+6, 24 to 27+6, 28 to 31+6, and 32 to 36+6 week intervals, respectively; (4) the detection rate for superimposed preeclampsia among women with chronic hypertension was similar to that in women without chronic hypertension, especially earlier in pregnancy, reaching at most 54% at 20 to 23+6 weeks (false-positive rate, 10%); and (5) prediction models performed comparably to the Fetal Medicine Foundation calculators when the same maternal risk factors and biomarkers (mean arterial pressure, placental growth factor, and soluble vascular endothelial growth factor receptor-1 multiples of the mean values) were used as input. CONCLUSION: We introduced prediction models for preeclampsia throughout pregnancy. These models can be useful to identify women at risk during the first trimester who could benefit from aspirin treatment or later in pregnancy to inform patient management. Relative to prediction performance at 8 to 15+6 weeks, there was a substantial improvement in the detection rate for preterm and term preeclampsia by using data collected after 20 and 32 weeks' gestation, respectively. The inclusion of plasma soluble endoglin improves the early prediction of superimposed preeclampsia, which may be valuable when Doppler velocimetry of the uterine arteries is not available.
引用
- Tarca AL, Taran A, Romero R, et al. Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study. Am J Obstet Gynecol. 2021. PMID: 34998477. doi:10.1016/j.ajog.2021.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。